Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: Is the action in the gut?

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 1983-1985

  Wool, Geoffrey D ^a   Reardon, Catherine A ^a   Getz, Godfrey S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; HIGH DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR RESPONSE; CHOLESTEROL TRANSPORT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HEART PROTECTION; LIPID ABSORPTION; MACROPHAGE; NONHUMAN; NOTE; PROTEIN DEGRADATION; ANIMAL; CHEMISTRY; FEMALE; METABOLISM;

ANIMALS; APOLIPOPROTEIN A-I; FEMALE; LIPOPROTEINS, HDL; NANOPARTICLES; RECEPTORS, LDL;

EID: 84907532877     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E053538     Document Type: Note

References (24)

1. Zhao, Y., A. S. Black, D. J. Bonnet, B. E. Maryanoff, L. K. Curtiss, L. J. Leman, and M. R. Ghadiri. 2014. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J. Lipid Res. 2053-2063.
2. Kono, M., T. Tanaka, M. Tanaka, C. Vedhachalam, P. S. Chetty, D. Nguyen, P. Dhanasekaran, S. Lund-Katz, M. C. Phillips, and H. Saito. 2010. Disruption of the C-terminal helix by single amino acid deletion is directly responsible for impaired cholesterol efflux ability of apolipoprotein A-I Nichinan. J. Lipid Res. 51: 809-818.
3. Wang, L., X. Mei, D. Atkinson, and D. M. Small. 2014. Surface behavior of apolipoprotein A-I and its deletion mutants at model lipoprotein interfaces. J. Lipid Res. 55: 478-492.
4. Anantharamaiah, G. M., V. K. Mishra, D. W. Garber, G. Datta, S. P. Handattu, M. N. Palgunachari, M. Chaddha, M. Navab, S. T. Reddy, J. P. Segrest, et al. 2007. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48: 1915-1923.
5. Getz, G. S., G. D. Wool, and C. A. Reardon. 2010. Biological properties of apolipoprotein A-I mimetic peptides. Curr. Atheroscler. Rep. 12: 96-104.
6. Amar, M. J., W. D'Souza, S. Turner, S. Demosky, D. Sviridov, J. Stonik, J. Luchoomun, J. Voogt, M. Hellerstein, and A. T. Remaley. 2010. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharmacol. Exp. Ther. 334: 634-641.
7. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105: 290-292.
8. Zhao, Y., T. Imura, L. J. Leman, L. K. Curtiss, B. E. Maryanoff, and M. R. Ghadiri. 2013. Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J. Am. Chem. Soc. 135: 13414-13424.
9. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. J. Lipid Res. 49: 1268-1283.
10. Wool, G. D., T. Vaisar, C. A. Reardon, and G. S. Getz. 2009. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res. 50: 1889-1900.
11. Sethi, A. A., J. A. Stonik, F. Thomas, S. J. Demosky, M. Amar, E. Neufeld, H. B. Brewer, W. S. Davidson, W. D'Souza, D. Sviridov, et al. 2008. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283: 32273-32282.
12. Nikoulin, I. R., and L. K. Curtiss. 1998. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J. Clin. Invest. 101: 223-234.
13. Bielicki, J. K., H. Zhang, Y. Cortez, Y. Zheng, V. Narayanaswami, A. Patel, J. Johansson, and S. Azhar. 2010. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J. Lipid Res. 51: 1496-1503.
14. Handattu, S. P., G. Nayyar, D. W. Garber, M. N. Palgunachari, C. E. Monroe, T. D. Keenum, V. K. Mishra, G. Datta, and G. M. Anantharamaiah. 2013. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis. 227: 58-64.
15. Van Lenten, B. J., A. C. Wagner, C. L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49: 2302-2311.
16. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, D. Garber, et al. 2004. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109: 3215-3220.
17. Navab, M., S. T. Reddy, G. M. Anantharamaiah, S. Imaizumi, G. Hough, S. Hama, and A. M. Fogelman. 2011. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res. 52: 1200-1210.
18. Chattopadhyay, A., M. Navab, G. Hough, F. Gao, D. Meriwether, V. Grijalva, J. R. Springstead, M. N. Palgnachari, R. Namiri-Kalantari, F. Su, et al. 2013. A novel approach to oral apoA-I mimetic therapy. J. Lipid Res. 54: 995-1010.
19. Navab, M., G. Hough, G. M. Buga, F. Su, A. C. Wagner, D. Meriwether, A. Chattopadhyay, F. Gao, V. Grijalva, J. S. Danciger, et al. 2013. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J. Lipid Res. 54: 3403-3418.
20. Navab, M., S. T. Reddy, G. M. Anantharamaiah, G. Hough, G. M. Buga, J. Danciger, and A. M. Fogelman. 2012. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J. Lipid Res. 53: 437-445.
21. Tardy, C., M. Goffinet, N. Boubekeur, R. Ackermann, G. Sy, A. Bluteau, G. Cholez, C. Keyserling, N. Lalwani, J. F. Paolini, et al. 2014. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 232: 110-118.
22. Smits, L. P., R. S. Kootte, and E. S. Stroes. 2014. Reversal of atherosclerosis with apolipoprotein A1: back to basics. Atherosclerosis. 232: 217-219.
23. Rader, D. J., and A. R. Tall. 2012. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18: 1344-1346.
24. Hewing, B., K. J. Moore, and E. A. Fisher. 2012. HDL and cardiovascular risk: time to call the plumber? Circ. Res. 111: 1117-1120.